ImmunoPrecise Antibodies Ltd. TQB.F Stock
ImmunoPrecise Antibodies Ltd. Price Chart
ImmunoPrecise Antibodies Ltd. TQB.F Financial and Trading Overview
ImmunoPrecise Antibodies Ltd. stock price | 0.98 EUR |
Previous Close | 2.58 EUR |
Open | 2.58 EUR |
Bid | 2.58 EUR x N/A |
Ask | 2.7 EUR x N/A |
Day's Range | 2.58 - 2.58 EUR |
52 Week Range | 2.18 - 6.26 EUR |
Volume | 225 EUR |
Avg. Volume | 81 EUR |
Market Cap | 64.33M EUR |
Beta (5Y Monthly) | 0.536971 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.39 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
TQB.F Valuation Measures
Enterprise Value | 62.98M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.1717858 |
Price/Book (mrq) | 1.0543523 |
Enterprise Value/Revenue | 3.105 |
Enterprise Value/EBITDA | -2.599 |
Trading Information
ImmunoPrecise Antibodies Ltd. Stock Price History
Beta (5Y Monthly) | 0.536971 |
52-Week Change | -28.38% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.26 EUR |
52 Week Low | 2.18 EUR |
50-Day Moving Average | 2.57 EUR |
200-Day Moving Average | 4 EUR |
TQB.F Share Statistics
Avg. Volume (3 month) | 81 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 24.94M |
Float | 20.85M |
Short Ratio | N/A |
% Held by Insiders | 1.55% |
% Held by Institutions | 5.72% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | April 30, 2022 |
Most Recent Quarter (mrq) | January 31, 2023 |
Next Fiscal Year End | April 30, 2023 |
Profitability
Profit Margin | -128.55% |
Operating Margin (ttm) | -129.41% |
Gross Margin | 55.85% |
EBITDA Margin | -119.47% |
Management Effectiveness
Return on Assets (ttm) | -23.62% |
Return on Equity (ttm) | -47.94% |
Income Statement
Revenue (ttm) | 20.28M EUR |
Revenue Per Share (ttm) | 0.85 EUR |
Quarterly Revenue Growth (yoy) | 7.39% |
Gross Profit (ttm) | 10.77M EUR |
EBITDA | -24233000 EUR |
Net Income Avi to Common (ttm) | -26075000 EUR |
Diluted EPS (ttm) | -0.74 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 11.32M EUR |
Total Cash Per Share (mrq) | 0.45 EUR |
Total Debt (mrq) | 7.48M EUR |
Total Debt/Equity (mrq) | 12.24 EUR |
Current Ratio (mrq) | 2.837 |
Book Value Per Share (mrq) | 2.447 |
Cash Flow Statement
Operating Cash Flow (ttm) | -19386000 EUR |
Levered Free Cash Flow (ttm) | -9563375 EUR |
Profile of ImmunoPrecise Antibodies Ltd.
Country | Germany |
State | BC |
City | Victoria |
Address | 3204–4464 Markham Street |
ZIP | V8Z 7X8 |
Phone | N/A |
Website | https://www.ipatherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 85 |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Q&A For ImmunoPrecise Antibodies Ltd. Stock
What is a current TQB.F stock price?
ImmunoPrecise Antibodies Ltd. TQB.F stock price today per share is 0.98 EUR.
How to purchase ImmunoPrecise Antibodies Ltd. stock?
You can buy TQB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ImmunoPrecise Antibodies Ltd.?
The stock symbol or ticker of ImmunoPrecise Antibodies Ltd. is TQB.F.
Which industry does the ImmunoPrecise Antibodies Ltd. company belong to?
The ImmunoPrecise Antibodies Ltd. industry is Biotechnology.
How many shares does ImmunoPrecise Antibodies Ltd. have in circulation?
The max supply of ImmunoPrecise Antibodies Ltd. shares is 27.13M.
What is ImmunoPrecise Antibodies Ltd. Price to Earnings Ratio (PE Ratio)?
ImmunoPrecise Antibodies Ltd. PE Ratio is now.
What was ImmunoPrecise Antibodies Ltd. earnings per share over the trailing 12 months (TTM)?
ImmunoPrecise Antibodies Ltd. EPS is -0.39 EUR over the trailing 12 months.
Which sector does the ImmunoPrecise Antibodies Ltd. company belong to?
The ImmunoPrecise Antibodies Ltd. sector is Healthcare.